secwatch.observer — SEC 8-K summary
======================================

Issuer:     MESA LABORATORIES INC /CO/ (MLAB)
CIK:        0000724004
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001437749-22-018743
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mesa Labs Q1: revenue up 44% but net loss of $1.4M; organic growth slows to 3%
------------------------------------------------------------------------------

- GAAP diluted EPS loss of ($0.27) vs prior-year EPS of $0.38; net loss of ($1.438M) from $1.995M income.
- Revenue $50.5M (+44% total, +3% organic); non-GAAP adjusted OI $6.158M (-33%) or $1.17/share.
- Clinical Genomics (29% rev) hit by China lockdowns; Sterilization & Disinfection down 2%.
- Biopharma Development grew 24%; Calibration Solutions fell 6% on supply chain shortages.
- Unusual items: $356K in Agena integration costs; management cites FX, labor, and material headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724004/000143774922018743/0001437749-22-018743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724004/000143774922018743/mlab20220803_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-018743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer